论文部分内容阅读
目的探讨雷贝拉唑联合莫沙必利治疗反流性食管炎(reflux esophagitis,RE)的临床疗效和安全性。方法将120例经胃镜证实的反流性食管炎患者随机分成治疗组和对照组。治疗组60例:口服雷贝拉唑10mg,1次/d,莫沙必利5mg,3次/d;对照组60例:口服奥美拉唑20mg,2次/d,莫沙必利5mg,3次/d。疗程均为6周,疗程结束后复查胃镜,观察镜下愈合率,并记录症状改善情况及不良反应。结果治疗1周后,治疗组和对照组临床症状改善总有效率分别为75%,46.7%,两组比较有显著性差异(P<0.01);6周后,治疗组和对照组临床症状改善总有效率、胃镜下有效率分别为95%,90%、93.3%,90%。两组差异均无统计学意义(P>0.05)。结论雷贝拉唑联合莫沙必利治疗反流性食管炎症状改善迅速,病变愈合率和症状改善率高,是治疗反流性食管炎安全、有效、理想的药物。
Objective To investigate the clinical efficacy and safety of rabeprazole combined with mosapride in the treatment of reflux esophagitis (RE). Methods 120 cases of reflux esophagitis confirmed by endoscopy were randomly divided into treatment group and control group. Treatment group of 60 patients: oral rabeprazole 10mg, 1 / d, mosapride 5mg, 3 times / d; control group of 60 patients: oral omeprazole 20mg, 2 times / d, mosapride 5mg , 3 times / d. The course of treatment was 6 weeks. After the course of treatment, the gastroscope was reviewed, the healing rate under the microscope was observed, and the symptom improvement and adverse reactions were recorded. Results After 1 week of treatment, the total effective rate of clinical symptoms improvement was 75% and 46.7% respectively in the treatment group and the control group, with significant difference between the two groups (P <0.01); after 6 weeks, the clinical symptoms in the treatment group and the control group were improved The total effective rate, gastroscopy effective rates were 95%, 90%, 93.3%, 90%. There was no significant difference between the two groups (P> 0.05). Conclusion Rabeprazole combined with mosapride treatment of reflux esophagitis symptoms improved rapidly, the rate of lesion healing and improvement of symptoms is high, is safe, effective and ideal for the treatment of reflux esophagitis.